Aditxt, Inc. reports developments as a life sciences and health-innovation platform with operating subsidiaries focused on diagnostics, precision oncology, and immune-system technologies. Company news includes updates on Ignite Proteomics, a commercial-stage precision oncology business that uses functional protein profiling to support cancer therapy selection, and Pearsanta, which is developing blood-based diagnostic tests including the Mitomic Endometriosis Test.
Recurring ADTX coverage also includes subsidiary leadership, clinical and research publications, acquisition activity, shareholder votes, reverse stock splits, Nasdaq listing matters, and other capital-structure actions tied to the company’s publicly traded common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.